193 related articles for article (PubMed ID: 38892809)
21. Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach.
Morató X; Pytel V; Jofresa S; Ruiz A; Boada M
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012569
[TBL] [Abstract][Full Text] [Related]
22. Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives.
Sun BL; Chen Y; Fan DY; Zhu C; Zeng F; Wang YJ
Sci China Life Sci; 2021 Jun; 64(6):926-937. PubMed ID: 33106917
[TBL] [Abstract][Full Text] [Related]
23. Modulation of cholesterol metabolism with Phytoremedies in Alzheimer's disease: A comprehensive review.
Koppula S; Wankhede NL; Sammeta SS; Shende PV; Pawar RS; Chimthanawala N; Umare MD; Taksande BG; Upaganlawar AB; Umekar MJ; Kopalli SR; Kale MB
Ageing Res Rev; 2024 Jun; 99():102389. PubMed ID: 38906182
[TBL] [Abstract][Full Text] [Related]
24. Regulation of neuroinflammation in Alzheimer's disease via nanoparticle-loaded phytocompounds with anti-inflammatory and autophagy-inducing properties.
Nayak V; Patra S; Rout S; Jena AB; Sharma R; Pattanaik KP; Singh J; Pandey SS; Singh RP; Majhi S; Singh KR; Kerry RG
Phytomedicine; 2024 Jan; 122():155150. PubMed ID: 37944239
[TBL] [Abstract][Full Text] [Related]
25. Role of tau protein in Alzheimer's disease: The prime pathological player.
Muralidar S; Ambi SV; Sekaran S; Thirumalai D; Palaniappan B
Int J Biol Macromol; 2020 Nov; 163():1599-1617. PubMed ID: 32784025
[TBL] [Abstract][Full Text] [Related]
26. Drug candidates in clinical trials for Alzheimer's disease.
Hung SY; Fu WM
J Biomed Sci; 2017 Jul; 24(1):47. PubMed ID: 28720101
[TBL] [Abstract][Full Text] [Related]
27. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
Elife; 2020 Jun; 9():. PubMed ID: 32510331
[TBL] [Abstract][Full Text] [Related]
28. DPP-4 inhibitors: a promising therapeutic approach against Alzheimer's disease.
Angelopoulou E; Piperi C
Ann Transl Med; 2018 Jun; 6(12):255. PubMed ID: 30069457
[TBL] [Abstract][Full Text] [Related]
29. Progress in the development of new drugs in Alzheimer's disease.
Piau A; Nourhashémi F; Hein C; Caillaud C; Vellas B
J Nutr Health Aging; 2011 Jan; 15(1):45-57. PubMed ID: 21267520
[TBL] [Abstract][Full Text] [Related]
30. Doxycycline for Alzheimer's Disease: Fighting β-Amyloid Oligomers and Neuroinflammation.
Balducci C; Forloni G
Front Pharmacol; 2019; 10():738. PubMed ID: 31333460
[TBL] [Abstract][Full Text] [Related]
31. Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update.
Yadollahikhales G; Rojas JC
Neurotherapeutics; 2023 Jul; 20(4):914-931. PubMed ID: 37490245
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
Pinheiro L; Faustino C
Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
[TBL] [Abstract][Full Text] [Related]
33. Exploring Dimethylsulfoniopropionate as a potential treatment for Alzheimer's disease: A study using the 3 × Tg-AD mouse model.
Sun F; Huang X; Wang H; Lin B; Li H; Wang X; Liu Q
Phytomedicine; 2024 Jul; 130():155788. PubMed ID: 38838634
[TBL] [Abstract][Full Text] [Related]
34. p110δ PI3-Kinase Inhibition Perturbs APP and TNFα Trafficking, Reduces Plaque Burden, Dampens Neuroinflammation, and Prevents Cognitive Decline in an Alzheimer's Disease Mouse Model.
Martínez-Mármol R; Mohannak N; Qian L; Wang T; Gormal RS; Ruitenberg MJ; Vanhaesebroeck B; Coulson EJ; Meunier FA
J Neurosci; 2019 Oct; 39(40):7976-7991. PubMed ID: 31363064
[TBL] [Abstract][Full Text] [Related]
35. An agnostic reevaluation of the amyloid cascade hypothesis of Alzheimer's disease pathogenesis: The role of APP homeostasis.
Caselli RJ; Knopman DS; Bu G
Alzheimers Dement; 2020 Nov; 16(11):1582-1590. PubMed ID: 32588983
[TBL] [Abstract][Full Text] [Related]
36. Tau in Alzheimer's Disease: Pathological Alterations and an Attractive Therapeutic Target.
Gu JL; Liu F
Curr Med Sci; 2020 Dec; 40(6):1009-1021. PubMed ID: 33428128
[TBL] [Abstract][Full Text] [Related]
37. Reduced Efficacy of Anti-Aβ Immunotherapy in a Mouse Model of Amyloid Deposition and Vascular Cognitive Impairment Comorbidity.
Weekman EM; Sudduth TL; Caverly CN; Kopper TJ; Phillips OW; Powell DK; Wilcock DM
J Neurosci; 2016 Sep; 36(38):9896-907. PubMed ID: 27656027
[TBL] [Abstract][Full Text] [Related]
38. Is Beta-Amyloid Accumulation a Cause or Consequence of Alzheimer's Disease?
Wang S; Mims PN; Roman RJ; Fan F
J Alzheimers Parkinsonism Dement; 2016; 1(2):. PubMed ID: 28815226
[TBL] [Abstract][Full Text] [Related]
39. Re-Arranging the Puzzle between the Amyloid-Beta and Tau Pathology: An APP-Centric Approach.
Haut F; Argyrousi EK; Arancio O
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203429
[TBL] [Abstract][Full Text] [Related]
40. Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns.
Lu D; Dou F; Gao J
Drug Discov Ther; 2023; 17(6):440-444. PubMed ID: 38220210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
